[{"id":"acb735f2-e0d3-48ef-9323-330de9633b97","acronym":"BGB-900-102","url":"https://clinicaltrials.gov/study/NCT03744468","created_at":"2021-01-18T18:20:22.768Z","updated_at":"2025-02-25T14:40:03.995Z","phase":"Phase 1/2","brief_title":"Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors","source_id_and_acronym":"NCT03744468 - BGB-900-102","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)"],"overall_status":"Completed","enrollment":" Enrollment 114","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 02/06/2025","primary_completion_date":" 02/06/2025","study_txt":" Completion: 02/06/2025","study_completion_date":" 02/06/2025","last_update_posted":"2025-02-14"},{"id":"ac22c3c9-66ab-4000-be70-b84ca8b1533a","acronym":"BGB-LC-201","url":"https://clinicaltrials.gov/study/NCT05635708","created_at":"2022-12-02T15:56:38.256Z","updated_at":"2025-02-25T16:18:24.125Z","phase":"Phase 2","brief_title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05635708 - BGB-LC-201","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • alcestobart (LBL-007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-31"},{"id":"32d50481-f20f-431a-b2dd-883c277275ba","acronym":"BGB-HNSCC-201","url":"https://clinicaltrials.gov/study/NCT05909904","created_at":"2023-06-18T17:07:58.901Z","updated_at":"2025-02-25T16:18:54.290Z","phase":"Phase 2","brief_title":"Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05909904 - BGB-HNSCC-201","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/21/2023","start_date":" 07/21/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-01-08"},{"id":"def7c0d3-011b-4e25-936d-9f3f6364ae6a","acronym":"Liberty-201","url":"https://clinicaltrials.gov/study/NCT05609370","created_at":"2022-11-08T14:56:34.793Z","updated_at":"2025-02-25T16:18:17.599Z","phase":"Phase 1/2","brief_title":"A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05609370 - Liberty-201","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • alcestobart (LBL-007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 01/29/2023","start_date":" 01/29/2023","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2026","study_completion_date":" 04/15/2026","last_update_posted":"2025-01-01"},{"id":"ea707ec7-5a15-4d00-85aa-eb195dfbadbf","acronym":"BGB-LC-202","url":"https://clinicaltrials.gov/study/NCT05577702","created_at":"2022-10-13T17:58:07.280Z","updated_at":"2025-02-25T16:18:14.799Z","phase":"Phase 2","brief_title":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05577702 - BGB-LC-202","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • alcestobart (LBL-007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 02/16/2023","start_date":" 02/16/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-18"}]